USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: PRESAGE BIOSCIENCES, INC.
Address: 530 Fairview Avenue North
Seattle, WA 98109-5553
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $288,692.00 1
STTR Phase I $164,492.00 1
STTR Phase II $1,210,192.00 1

Award List:

Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Fred Hutchinson Cancer Research Center
Principal Investigator: James M. Olson – 206-667-7955
Award Amount: $164,492.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific… More

Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency: HHS
Research Institution: FRED HUTCHINSON CANCER RESEARCH CENTER
Principal Investigator: James M. Olson – (206) 667-7955
Award Amount: $1,210,192.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific… More

Phase II of VerOFy: A New Tool to Improve Productivity for Stress Research

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard Klinghoffer – 206-667-6826
Award Amount: $288,692.00
Abstract:
DESCRIPTION (provided by applicant): With few exceptions, extensive characterization of signal pathway alterations in cancer, and advances in our capacity to identify potent modulators of distinct molecular targets, has not translated into breakthrough drugs. In a recent New York Times article (Nov.… More